Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Mucopolysaccharidosis II Clinical Trial

Official title:

Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03153319
• Other study ID #: 31041-01
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: June 5, 2017
• Est. completion date: June 2026

Study information

• Verified date: March 2023
• Source: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

Description:

This study is a randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI. Children and adults diagnosed with MPS I, II or VI, with significant joint restrictions and pain will be randomized to adalimumab treatment or placebo treatment for the first 16 weeks. This will be followed by a 32-week open label adalimumab treatment phase.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: June 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

• Male or female =5 years of age;

• Diagnosis of MPS I, II or VI;

• Treatment with ERT for =1 year or no treatment with ERT for =1 year;

• Weight =15 kg;

• Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean);

• = 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.

Exclusion Criteria:

• History of HCT less than 2 years prior to enrollment;

• Immune suppression therapy less than 1 year prior to enrollment;

• Active graft versus host disease;

• Current diagnosis or history of lymphoma or other malignancy;

• Current active infection;

• History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);

• Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB

• Congestive heart failure defined by an ejection fracture <50% measured by ECHO;

• Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);

• Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);

• Hepatitis B infection (active or chronic carrier);

• Latex sensitivity;

• Pregnancy or breastfeeding;

• Known or suspected allergy to adalimumab or related products;

• Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;

• Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or

• Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.

Related Conditions & MeSH terms

• Mucopolysaccharidoses
• Mucopolysaccharidosis I
• Mucopolysaccharidosis II
• Mucopolysaccharidosis VI

Intervention

Drug:
• Adalimumab Injection [Humira]
Investigational Drug
• Saline Solution for Injection
Placebo Comparator

Locations

Country	Name	City	State
United States	The Lundquist Institute at Harbor-UCLA Medical Center	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain - 16 weeks	Mean difference in bodily pain measured by the Children's Health Questionnaire - Parent Form 50 (CHQ-PF50) or the Medical Outcomes Study - Short Form 36 (SF-36) in treatment versus placebo at 16 weeks	16 weeks
Primary	Adalimumab trough	Percentage of subjects who achieve a goal trough concentration of adalimumab with every other week dosing	32 weeks
Secondary	Joint range-of-motion - 16 weeks	Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion in treatment versus placebo at 16 weeks.	16 weeks
Secondary	Pain - 52 weeks	Mean difference in bodily pain measured by the CHQ-PF50 or the SF-36 at 52 weeks compared to baseline.	52 weeks
Secondary	Joint range-of-motion - 52 weeks	Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion at 52 weeks compared to baseline.	52 weeks
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability	Percentage of subjects who develop an AE and/or SAE	52 weeks